Additional new PDE4 inhibitors are in development for psoriasis, such as Hemay005 [123], Orismilast [124] and MK-0873 [125], while GW842470X [126] and DRM02 for AD [127]; the latter have recently completed phase II as for AD and for rosacea (see Table 2). Here, PDE4A is linked to psoriasis.